Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells.

Acta pharmacologica Sinica - 1 Jan 2014

He Chang-xi, Ai Jing, Xing Wei-qiang, Chen Yi, Zhang Hao-tian, Huang Min, Hu You-hong, Ding Jian, Geng Mei-yu

Abstract excerpt

AIM: c-Met kinase deregulation is strongly associated with the formation, progression and dissemination of human cancers. In this study we identified Yhhu3813 as a small-molecule inhibitor of c-Met kinase and characterized its antitumor properties both in vitro and in vivo. METHODS: The activities of different kinases were measured using ELISA assays and signaling proteins in the cells were detected with Western...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dogs
Share to HCT116 Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HT29 Cells

Share to Madin Darby Canine Kidney Cells

Share to Neoplasm Invasiveness

Share to Proto-Oncogene Proteins c-met

Share to Random Allocation

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 24241352
DOI: 10.1038/aps.2013.125
PMCID: PMC4075751

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells.PMID 24241352Read ↗

Targeting the c-MET signaling pathway for cancer therapySemantic proximity Read ↗

Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical CandidatesSemantic proximity Read ↗

Targeting the c-Met Signaling Pathway in CancerSemantic proximity Read ↗

Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer.Semantic proximity Read ↗

Targeting MET Dysregulation in CancerSemantic proximity Read ↗

Targeting mesenchymal-epithelial transition factor signaling in cancer: from genetic alterations to clinical advances and future prospects.Semantic proximity Read ↗

NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants.Semantic proximity Read ↗

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.Semantic proximity Read ↗

MET receptor tyrosine kinase as a therapeutic anticancer target.Semantic proximity Read ↗

MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review.Semantic proximity Read ↗

ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor ActivitySemantic proximity Read ↗

Forty‐nine gastric cancer cell lines with integrative genomic profiling for development of c‐MET inhibitorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.